SCHEMBL3315531

SCHEMBL3315531

c1cnc(-c2cccn3ccnc23)nc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.42
PDE10A Q9Y233 1/20 0.34
TDP2 O95551 1/20 0.33
NSD2 O96028 1/20 0.33
ABL1 P00519 1/20 0.33
PLCG1 P19174 1/20 0.33
CES1 P23141 1/20 0.33
PAX8 Q06710 1/20 0.33
RIN1 Q13671 1/20 0.33
MEN1 O00255 1/20 0.33
THRB P10828 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
GAA P10253 1/20 0.33
NTRK1 P04629 1/20 0.33
ALDH1A2 O94788 1/20 0.33
ALDH1A3 P47895 1/20 0.33
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7311083 0.79 KDM4E (0.45) NUDT1PDE10ABLMTDP1ALDH1A2
SCHEMBL4672079 0.78 ALDH1A3 (0.54) NUDT1ALDH1A2ALDH1A3
SCHEMBL7308381 0.78 JAK2 (0.50) NUDT1ALDH1A2ALDH1A3
SCHEMBL3837547 0.76 NUDT1 (0.38) NUDT1PDE10AALDH1A2ALDH1A3
SCHEMBL30627465 0.74 NUDT1 (0.37) NUDT1PDE10ATDP1ALDH1A2ALDH1A3
SCHEMBL2900371 0.74 CCNE2 (0.47) NUDT1ABL1ALDH1A2ALDH1A3
SCHEMBL7311707 0.74 KDR (0.48) NUDT1ABL1KMT2AALDH1A2ALDH1A3
SCHEMBL7317792 0.74 ALDH1A3 (0.54) NUDT1MEN1KMT2ATDP1GAA
SCHEMBL1431759 0.74 TNKS (0.47) NUDT1PDE10AMEN1KMT2AGAA
SCHEMBL7318740 0.73 ALDH1A1 (0.44) ALDH1A2ALDH1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010049731-A1 PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-05-06 WO disclosed
US-20100105655-A1 NOVEL COMPOUNDS 515 ASTRAZENECA AB 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105655-A1 NOVEL COMPOUNDS 515 TYMS, ABCG2, UMPS NUDT1 44/4885PDE10A 280/4885TDP2 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.